Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by mstrmndson Apr 23, 2024 1:09am
2391 Views
Post# 36002656

Germ of a Plan - $20 million USD

Germ of a Plan - $20 million USDGERM OF A PLAN FOR MADMAN OSBORNE:

1. Citagenix - 1) request sale proceeds early or 2) transfer sale agreement payout to Nuance
2. SRED credits - 1) early filings and urgent request 2) transfer proceeds to Nuance (2023-2025)
3. Property (yorkville building) - 1) sell property and pay Nuance

This could generate about $10 million USD

4. Terminations - non-employees terminated
5. Terminations - employees FT staff to PT

Reduce burn by 50-75% and shelter the company from Ontario employment law jackers.

6. Leverage debt solutions - if borrowing >>> all other solutions then borrow the difference to pay Nuance out in tranches tied to milesstones 1) pre-positive FDA 2) post-positive FDA 3) pre-clinical trial 4) post-clinical trial

If the company needs to raise $10 million among D & O, insiders, etc, then they need to pony up.  There's no choice.  Directors personal assets are liable to creditors (assuming they have D & O insurance).  If Dan needs to sell the ranch to bridge the company, then GIDDY UP!  Leverage the D & O policy to bridge the company!

7. Fight the $4 million USD in legal fees.  This is no time to be stoic.  Appeal the entire thing on the basis of the definition of "material" which predicates the Health Canada confidential disclosure optics.  Fraudlent misrepresentation is a VERY damaging and vexatious claim if it's predicated on the definition of "material."  This vexatious claim framed Antibe as "hiding" information infront of intentionally paranoid arbitrators (biased towards Nuance) when the threshhold for "material" was not met.  If the communications were not "material" then confidential disclosure is not obligatory and is actually defined by their CDA.  If the CDA did not define "material" explicitly then it is subject to interpretation.  Any DUMBASS JUDGE would understand that if non-material speculation were disclosed to Nuance and Health Canada did not intervene, then there would be obvious harm to purely speculative disclosure.  Nuance should know based on the data room that there were prior concerns with LTE.  Therefore this is not new.  At their own risk, Nuance accepted the deal as part of a pre-IPO pump.  

Plant the Nuance CEO as being a liar.  PROVE IT.  Cast doubt on the authenticity of the binding arbitration results and APPEAL the entire thing.  Nuance wanted their money back and the only thing they could find to get it back are Health Canada communications from 2021.  If the Nuance CEO is a liar and he backdoored the deal with binding arbitration in Singapore and Nuance proved they are willing to destroy Antibe to get their money back now, and at the time of the sloppy deal they didn't even review 1/5 of the data room, what does that tell you???

CONTROL THE LEGAL NARRATIVE DAN!!  FRAME THE NUANCE CEO AND CAST DOUBT!!  WHEN NUANCE RAISED MONEY THEY NEEDED TO INVEST THAT MONEY RIGHT AWAY HENCE THE SLOPPY RUSHED DEAL.  SO THEY EQUALLY BENEFITTED FROM THE HASTE, EQUALLY ACCEPTED THE RISKS & IT'S OBVIOUS BECAUSE NUANCE COVERED THEMSELVES WITH BUDDIES IN SINGAPORE UNDER THE TERMS OF THE DEAL.  NUANCE WAS LOOKING FOR AN OUT TO GET THEIR MONEY BACK.  HOW FAR WERE THEY WILLING TO GO??  FAR ENOUGH TO DESTROY THE ANTIBE PIPELINE SHOULD RAISE RED FLAGS TO EVEN MORON JUDGES.  IT'S BAIT ON A HOOK.  STUPID OSBORNE!


-----------------------

Current cash: $19 million CAD
Nuance debt: $20 milion USD (legal excluded)
Projected revenue from #1-3: $10 million USD
Debt solution: $10 million USD
Any deficitis paid out by cash balance (compensated by burn reduction in company) tied to milestones

----------------------

DAN NEEDS TO STATE THE GERM OF A PLAN CLEARLY TO THESE DUMB JUDGES THEN SLAP HIS **** ON THE TABLE AND OFFER NUANCE THE FINAL OPTION TO TRANSFER THE DEAL TO ACUTE (PLAN B IN COURT) OR TAKE THEIR $$$ & COURT ORDERED PAYMENT TERMS AND **** OFF!




<< Previous
Bullboard Posts
Next >>